Phase 3 study with baxdrostat in uncontrolled or treatment-resistant hypertension meets primary endpoint
In the phase 3 BaxHTN trial, treatment with baxdrostat reduced systolic blood pressure (SBP) in patients with uncontrolled or treatment-resistant hypertension compared with placebo.
Positive results from the phase 3 BaxHTN trial, in which the effects of the aldosterone synthase inhibitor baxdrostat were evaluated, have been announced. Treatment with baxdrostat at two doses (2 mg and 1 mg) significantly reduced the primary outcome of mean seated SBP compared with placebo at 12 weeks. The trial also met all secondary endpoints.
BaxHTN is a multicenter, randomized, double-blinded, placebo-controlled, parallel group trial in which 796 patients with uncontrolled hypertension (treated with two different antihypertensive medications) or treatment-resistant hypertension (treated with three or more different antihypertensive medications, one being a diuretic) were randomized in a 1:1:1 ratio to baxdrostat 2 mg, 1 mg or placebo once daily, on top of standard of care.
The safety profile of baxdrostat in BaxHTN was favorable.
Full results from BaxHTN will be presented at the ESC Congress 2025.